CD8A and neoplasm: TMP195, an HDAC Class IIa inhibitor, may transform tumor-infiltrating monocytes and macrophages into cells able to sustain a robust CD8+ T-cell-mediated anti-tumor immune response in breast cancer and reduce metastasis [115, 116].